Ritesh Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ritesh Kumar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Abhilasha Gupta
Research Scholar Department of Chemistry School of Basic and Applied Sciences Career Point University Kota
1 shared publication- Anasuya Patil
Department of Pharmaceutics II Block Rajajinagar KLE College of Pharmacy Bengaluru
1 shared publication Jashanjit Singh
Gurukul Institute of Pharmaceutical Sciences Badesh Kalan Khamanon Fatehgarh Sahib Punjab
1 shared publicationKottappadathu Pillanayil
Professor and Principal Angadippuram (Po) Moulana College Of Pharmacy Perinthalmanna Malappuram Dist 679321 Kerala
1 shared publication- Manish Ramesh Bhise
Department of Pharmaceutics, SGSPS, Institute of Pharmacy, Akola (MS), Affiliated to Sant Gadge Baba Amravati University
1 shared publication - Mohammed Haneefa1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Sakun Publishing House
- Vol. 24 (5s) , 794-801
Design And Development Of Glimepiride Sustained-Release Implants For Long-Term Glycemic Control
Objective: To design and develop sustained-release (SR) glimepiride implants enabling long-term glycemic control with minimized burst release and improved adherence. Methods: Biodegradable PLGA-based in situ forming implants were engineered with solvent-induced phase inversion, using N-methyl-2-pyrrolidone as the primary solvent and polyethylene glycol as a plasticizer to modulate matrix porosity and initial drug efflux. A response-surface design optimized polymer concentration, plasticizer level, and co-solvent ratio to balance burst control and sustained kinetics. Formulations were characterized by SEM, in vitro release profiling over 28 days, and in vivo pharmacokinetics/pharmacodynamics in diabetic rodent models versus oral glimepiride. Results: Increasing PLGA and PEG content reduced surface porosity and attenuated the initial burst while sustaining release, achieving near-zero-order kinetics post-induction. Optimized implants curtailed 2–24h burst and provided depot activity for up to 14 days in vivo, maintaining plasma levels comparable to safe exposures from marketed tablets while prolonging glucose-lowering effects. Embedding glimepiride in nanoparticulate/triblock matrices within PLGA systems further refined release control and depot performance. Design principles and strategies align with contemporary advances in PLGA implant engineering to mitigate burst and enhance completeness of release. Conclusion: Glimepiride SR implants based on optimized PLGA in situ systems offer a feasible depot approach for extended glycemic control, with controlled burst, sustained therapeutic exposure, and potential to improve adherence and outcomes in type 2 diabetes.
- 1 January 2025
- Published by Sakun Publishing House
- Vol. 24 (5s) , 794-801
Open AccessDesign And Development Of Glimepiride Sustained-Release Implants For Long-Term Glycemic Control
Objective: To design and develop sustained-release (SR) glimepiride implants enabling long-term glycemic control with minimized burst release and improved adherence. Methods: Biodegradable PLGA-based in situ forming implants were engineered with solvent-induced phase inversion, using N-methyl-2-pyrrolidone as the primary solvent and polyethylene glycol as a plasticizer to modulate matrix porosity and initial drug efflux. A response-surface design optimized polymer concentration, plasticizer level, and co-solvent ratio to balance burst control and sustained kinetics. Formulations were characterized by SEM, in vitro release profiling over 28 days, and in vivo pharmacokinetics/pharmacodynamics in diabetic rodent models versus oral glimepiride. Results: Increasing PLGA and PEG content reduced surface porosity and attenuated the initial burst while sustaining release, achieving near-zero-order kinetics post-induction. Optimized implants curtailed 2–24h burst and provided depot activity for up to 14 days in vivo, maintaining plasma levels comparable to safe exposures from marketed tablets while prolonging glucose-lowering effects. Embedding glimepiride in nanoparticulate/triblock matrices within PLGA systems further refined release control and depot performance. Design principles and strategies align with contemporary advances in PLGA implant engineering to mitigate burst and enhance completeness of release. Conclusion: Glimepiride SR implants based on optimized PLGA in situ systems offer a feasible depot approach for extended glycemic control, with controlled burst, sustained therapeutic exposure, and potential to improve adherence and outcomes in type 2 diabetes.